Catalyst Pharmaceutical CPRX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's change in accrued liabilities?
- Catalyst Pharmaceutical (CPRX) reported change in accrued liabilities of -$9.21M in Q1 2026.
- How has Catalyst Pharmaceutical's change in accrued liabilities changed year-over-year?
- Catalyst Pharmaceutical's change in accrued liabilities decreased by 260.8% year-over-year, from -$2.55M to -$9.21M.
- What is the long-term trend for Catalyst Pharmaceutical's change in accrued liabilities?
- Over 3 years (2022 to 2025), Catalyst Pharmaceutical's change in accrued liabilities has grown at a 13.8% compound annual growth rate (CAGR), from $16.39M to $24.16M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.